gutflix
GI learning, personalised

Summary

COMPARISON OF DRUGS FOR EOSINOPHILIC ESOPHAGITIS: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Edoardo Vincenzo Savarino

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

A network meta-analysis of 13 randomized controlled trials involving 1327 subjects with eosinophilic esophagitis found that while most drugs achieve histological remission, few demonstrate superiority over placebo for symptomatic or endoscopic improvement.

KEY POINTS

- Budesonide orally disintegrating tablet 1mg twice daily ranked first for histological remission defined as 15 or fewer eosinophils per high-power field, followed by fluticasone orally disintegrating tablet 1.5mg twice daily and 3mg twice daily, and dupilumab 300mg weekly.
- EoE-specific formulations were generally superior to adapted asthma medications in achieving histological remission.
- Only budesonide orally disintegrating tablet 1mg twice daily and budesonide oral suspension 2mg twice daily were significantly more efficacious than placebo for symptom improvement.
- For endoscopic improvement based on the EoE endoscopic reference score, only budesonide orally disintegrating tablet 1mg twice daily and budesonide oral suspension 1mg or 2mg twice daily were significantly superior to placebo.
- This analysis is relevant for clinicians seeking evidence-based guidance on drug selection for adults and adolescents with active eosinophilic esophagitis.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/5c213ecc-743b-11ee-a714-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.